



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(Use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Application Number	10/675,980
Filing Date	September 30, 2003
First Named Inventor	Yaron Ilan
Art Unit	1648
Examiner Name	Michelle S. Horning
Attorney Docket Number	Enz-64(CIP)

[illegible][illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/675,980
Filing Date	September 30, 2003
First Named Inventor	Yaron Ilan
Art Unit	1648
Examiner Name	Michelle S. Horning
Attorney Docket Number	Enz-64(CIP)

Sheet

2

of

5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		See attached pages 3, 4 and 5.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Application No. 10/675,980

Filing Date: September 30, 2003

First Named Inventor: Ilan et al.

Art Unit: 1648

Examiner Name: Michelle S. Horning

Attorney Docket Number: Enz-64(CIP)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
	8	Dwek, RA., Block, TM, Nichita-Branza, N., Petrescu, S., Platt, F., Rudd, PM, Zitzmann, N., "Abnormal glycosylation in disease and therapy", Proceedings of the Royal Society of Medicine's 5 th Jenner Symposium (Glycobiology and Medicine conference), July 10-11, 2000	
	9	Axford. Glycobiology & Medicine: A millennial Review, July 2000	
	10	Beecher, WC, Metabolic profiling: Its role in biomarker discovery and gene function analysis, Chapter 17: The human metabolome. Kluwer Academic, 2003	
	11	Margalit et al. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am. J. Physiol. Gastrointest. Liver Physiol., November 2005, Abstract	
	12	Margalit et al. Amelioration of hepatic fibrosis via beta-glucoceramide mediated immune modulation is associated with NKT lymphocyte distribution and a cytokine shift. Am. Assoc. For Study of Liver Diseases, Meeting, November 2005	
	13	Margalit et al. Suppression of hepatocellular carcinoma by glucocerebroside is associated with altered NKT and CD8+ lymphocyte distributions, stat1 expression, lack of stat6 expression and a Th1 type immune response. Am Assoc. For Disease of Liver, October 200, Abstract	
	14	Zigmond et al., Facilitation of hapatocellular carcinaoma growth in mice by double negative NKT regulatory lymphocytes is inhibited by ex vivo exposure to beta-glucosylceramide. Am Assoc. for Study of Liver Diseases, Meeting, November 2005	
	15	Knipe, DM, Howley, PM, eds. Fields virology. 4 th ed. Vol. 1. Philadelphia: Lippincott Williams & Wilkins, 2001, 1004-1016 and 1127-1161	
	16	Hahn. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Current opinion in immunology, 2003, Vol.15, 443-449	
	17	De Francesco et al., Challenges and successes in developing new therapies of hepatitis C. Nature, 2005, Vol. 436, 953-960	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 4 of 5

Application No. 10/675,980

Filing Date: September 30, 2003

First Named Inventor: Ilan et al.

Art Unit: 1648

Examiner Name: Michelle S. Horning

Attorney Docket Number: Enz-64(CIP)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
	18	Schoenfeld, Y., et al, "Gaucher's disease: a disease with chronic stimulation of the immune system," Arch Pathol Lab Med 106(8):388-391 (1982);	
	19	Lichtenstein, et al, "Cytokine mRNA in Gaucher Disease," Blood Cells, Molecules and Diseases 23(19):395-401 (1997)	
	20	Barak, V., et al, "Cytokines in Gaucher's Disease," Eur. Cytokine Netw. 10(2):205-210 (1999)	
	21	Hollak, CEM, et al, "Elevated Levels of M-CSF, sCD14 and IL8 in Type 1 Gaucher Disease," Blood Cells, Molecules and Diseases 23(11):201-212 (1997)	
	22	Allen, MJ, et al, "Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10," Q. J. Med. 90(1):19-25 (1997)	
	23	Deibener, J., et al, "Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease," Haematologica 83:479-480 (1998)	
	24	Lachman, et al, "Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features," Q. J. Med 93:237-244 (2000)	
	25	Kawano, et al, "CD1d-Restricted and TCR-Mediated Activation of V _a 14 NKT Cells by Glycosylceramides," Science 278:1626-1629 (1997)	
	26	Burdin, N., et al, "Selective Ability of Mouse CD1 to Present Glycolipids: α -Galactosylceramide Specifically Stimulates V _a 14 ⁺ NK T Lymphocytes," J. Immunol 161:3271-3281 (1998)	
	27	Roy-Chowdhury, et al, U.S. Patent Application Serial No. 08/808,629 filed February 28, 1997	
	28	Roy-Chowdhury, et al, U.S. Patent Application Serial No. 09/356,294 filed on July 16, 1999, specification subsequently published in U.S. Patent Application No. 2003-0170258-A1, published September 11, 2003	
	29	Rabbani, et al, European Patent Application 1 072 271 A2, published January 31, 2001	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 5 of 5

Application No. 10/675,980

Filing Date: September 30, 2003

First Named Inventor: Ilan et al.

Art Unit: 1648

Examiner Name: Michelle S. Horning

Attorney Docket Number: Enz-64(CIP)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
	30	Hollak, et al, "Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease," J. Clin. Invest. 93(3):1288-1292 (1994)	
	31	Ferrari, C., et al, "Immunopathogenesis of hepatitis C virus infection," J. Hepatol 31s1:31-38 (1999)	
	32	Cerny, A., et al, "Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence," Hepatology 30(3):595-601 (1999)	
	33	Rehermann, B., "Cellular immune response to the hepatitis C virus," J. Viral Hepat. 6s1:31-35 (1999)	
	34	Gotsman, I., et al, "Induction of oral tolerance towards hepatitis B envelope antigens in a murine model," Antiviral Research 48:17-26 (2000)	
	35	Akbar, SM, et al, "Low responsiveness of hepatitis B virus-transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen presenting activity of dendritic cells", Immunology 78(3):468-475 (1993)	
	36	The complete listing of diseases is retrieved from http://www.mic.ki.se/Diseases/Alphalist.html .	
	37	Takahashi, M., Nakamura, K., Honda, K., Kitamura, Y., Mitzutani, T., Araki, Y., Kabemura, T., Chijiwa, Y., Harada, N., Nawata, H., "An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis", Dig Dis Sci. 2006 April 51(4): 677-86, (Abstract only)	
	38	Bode, JG., Ludwig, S., Ehrhardt, C., Albrecht, U., Erhardt, A., Schaper, F., Heinrich, PC, Haussinger, D., "IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3", FASEB J. 2003 March; 17(3):488-90 Epub 2003 Jan 22.	